Answers are grounded in this paper and cite their sources.
SUMMARY Recombinant activated coagulation factor VII (rFVIIa, NovoSeven®) is indicated for the treatment of bleeding episodes or as a prophylactic hemostatic agent during surgery in patients with inhibitor‐complicated hemophilia. Currently, the use of rFVIIa for indications other than hemophilia is being investigated in clinical trials. The original idea behind the development of rFVIIa was that it would function via enhancement of tissue factor‐dependent coagulation. However, the effects of rFVIIa on hemostasis proved to be more complex than initially anticipated. This paper summarizes current data and hypotheses on the mechanism of action of rFVIIa, providing a general model for the molecular basis for the efficacy of rFVIIa in its different applications.
No takes yet. Share an insight, caveat, or question.
Lisman et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: